James Proulx

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

H. Bachelez, P.C.M. van de Kerkhof, Robert Strohal et al. · The Lancet · 2015 · 394 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

Kim Papp, Alan Menter, Mai Abe et al. · British Journal of Dermatology · 2015 · 322 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis

Megan E. B. Clowse, Steven R. Feldman, John D. Isaacs et al. · Drug Safety · 2016 · 147 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

Robert Bissonnette, Lars Iversen, Howard Sofen et al. · British Journal of Dermatology · 2014 · 146 citations

Medicine, Pharmacology, Pharmacotherapy +14

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

H. Bachelez, P.C.M. van de Kerkhof, Robert Strohal et al. · HAL (Le Centre pour la Communication Scientifique Directe) · 2015 · 17 citations

Medicine, Pharmacology, Pharmacotherapy +8